FH 2001
Alternative Names: FH-2001Latest Information Update: 04 Oct 2022
At a glance
- Originator Shanghai Fosun Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 04 Oct 2022 Phase-II clinical trials in Solid tumours (Late-stage disease) in China (PO) prior to October 2022 (Shanghai Fosun Pharmaceutical pipeline, October 2022)
- 19 Apr 2022 Preclinical trials in Solid tumours in China (PO)
- 19 Apr 2022 Shanghai Fosun Pharmaceutical plans a phase I trial in Solid tumours (Late-stage disease) in China (Shanghai Fosun Pharmaceutical pipeline, April 2022)